Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management
Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic
malignancies. Two CAR T-cell products are now approved for clinical use by the US FDA …
malignancies. Two CAR T-cell products are now approved for clinical use by the US FDA …
Recent trends in cancer therapy: A review on the current state of gene delivery
Cancer treatment has been always considered one of the most critical and vital themes of
clinical issues. Many approaches have been developed, depending on the type and the …
clinical issues. Many approaches have been developed, depending on the type and the …
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
Chimeric antigen receptor T (CAR-T) cell therapy is an emerging and effective cancer
immunotherapy. Especially in hematological malignancies, CAR-T cells have achieved …
immunotherapy. Especially in hematological malignancies, CAR-T cells have achieved …
[HTML][HTML] Immunotherapy in ovarian cancer
Immunological destruction of tumors is a multistep, coordinated process that can be
modulated or targeted at several critical points to elicit tumor rejection. These steps in the …
modulated or targeted at several critical points to elicit tumor rejection. These steps in the …
Modulation of immune tolerance via siglec-sialic acid interactions
One of the key features of the immune system is its extraordinary capacity to discriminate
between self and non-self and to respond accordingly. Several molecular interactions allow …
between self and non-self and to respond accordingly. Several molecular interactions allow …
The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19
Thirty years after initial publications of the concept of a chimeric antigen receptor (CAR), the
US Food and Drug Administration (FDA) approved the first anti-CD19 CAR T-cell therapy …
US Food and Drug Administration (FDA) approved the first anti-CD19 CAR T-cell therapy …
Immunotherapy with CAR‐modified T cells: toxicities and overcoming strategies
S Sun, H Hao, G Yang, Y Zhang… - Journal of immunology …, 2018 - Wiley Online Library
T cells modified via chimeric antigen receptors (CARs) have emerged as a promising
treatment modality. Unparalleled clinical efficacy recently demonstrated in refractory B‐cell …
treatment modality. Unparalleled clinical efficacy recently demonstrated in refractory B‐cell …
A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies
To date, two chimeric antigen receptors (CAR)-T cell products from autologous T cells have
been approved by The United States Food and Drug Administration (FDA). The case-by …
been approved by The United States Food and Drug Administration (FDA). The case-by …
Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia
We and others previously reported potent antileukemia efficacy of CD123-redirected
chimeric antigen receptor (CAR) T cells in preclinical human acute myeloid leukemia (AML) …
chimeric antigen receptor (CAR) T cells in preclinical human acute myeloid leukemia (AML) …
CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells
Chimeric antigen receptor (CAR) T-cells targeting CD19 demonstrated remarkable efficacy
for the treatment of B-cell malignancies. The development of CAR T-cells against T-cell …
for the treatment of B-cell malignancies. The development of CAR T-cells against T-cell …